The key to driving down costs, or at the very least making costs more predictable, is integrating pathways into the Oncology Care Model program, said John L. Fox, MD, MS, associate vice president of medical affairs at Priority Health.
The key to driving down costs, or at the very least making costs more predictable, is integrating pathways into the Oncology Care Model program, said John L. Fox, MD, MS, associate vice president of medical affairs at Priority Health.
Transcript (slightly modified)
Can we draw parallels between payer-driven clinical pathways and the Oncology Medical Home model?
Medicare's Oncology Care Model, which I’m not an expert on, I think has a potential to drive down the cost of healthcare without impacting patient outcomes. There are a number of ways that can happen. One is that the cost of care will become more predictable because the regimens that providers use will have a more predictable cost.
In our experience with our Oncology Medical Home Initiative, where we ask providers to develop pathways around high-volume conditions and not only pathways but preferred regimens, we very clearly showed that providers tended to choose the less costly regimens. So I think that integration of pathways into an oncology care model program is not only essential, but that’s what will help drive down costs, at least make costs more predictable.
But more importantly, I think the pathways have to include or embed advanced care planning. The trends for increasing costs of drugs don’t suggest that will drive down the costs of care simply by having pathways. But if those pathways include discussions of patient preferences and goals of care, then I think it increases the likelihood that will diminish the amount of chemotherapy we’ll give to patients at the end-of-life because they’ll have said, my goals can be obtained in ways other than chemotherapy.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More